Database Query Results : , ,

Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
1- Aco,    Acoschimperoside P, 2'-acetate: a Hedgehog signaling inhibitory constituent from Vallaris glabra
- in-vitro, PC, PANC1 - in-vitro, Pca, DU145
HH↓, PTCH1↓, Bcl-2↓, Gli1↓,
147- AG,  EGCG,  CUR,    Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, MCF-7
Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓,
2646- AL,    Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress
- in-vitro, Pca, DU145 - in-vitro, Melanoma, RPMI-8226
AntiCan↑, eff↓, ChemoSen↑, ER Stress↑, tumCV↓, DNAdam↑, GSH∅, HSP70/HSPA5↓, UPR↑, β-catenin/ZEB1↓, ROS↑, HO-2↑, SIRT1↑, GlucoseCon∅, lactateProd∅, chemoP↑,
282- ALA,    Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression
- in-vitro, Pca, PC3
MMP↓, Casp↑, MMP9↓,
277- ALA,    α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
ROS↑, Hif1a↑, JNK↑, Casp3↑, P21↑, BAX↑, Bcl-xL↓, cFos↓,
265- ALA,    Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ROS↓, SOD↓, GSTP1/GSTπ↓, NRF2↓, p62↓, p62↑, SOD↑, p‑mTOR↑, Beclin-1↓, ROS↑, SOD1↑,
3442- ALA,    α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B - in-vitro, Nor, 3T3
tumCV↓, TumCMig↓, TumCI↓, ROS↑, Hif1a↑, JNK↑, Casp↑, TumCCA↑, Apoptosis↑, selectivity↑,
1151- Api,    Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study
- in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
581- Api,  Cisplatin,    The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
- in-vitro, Pca, CD44+
Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,
208- Api,    Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer
- in-vivo, Pca, PC3 - in-vivo, Pca, DU145
XIAP↓, survivin↓, Bcl-xL↓, Bcl-2↓, BAX↑,
240- Api,    The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling
- in-vitro, Pca, PC3 - in-vitro, Pca, CD44+
P21↑, p27↑, Casp3↑, Casp8↑, Slug↓, Snail↓, NF-kB↓, PI3K↓, Akt↓,
238- Api,    Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,
237- Api,    Apigenin blocks IKKα activation and suppresses prostate cancer progression
- in-vivo, Pca, PC3 - in-vivo, Pca, 22Rv1 - in-vivo, Pca, LNCaP - in-vivo, Pca, DU145
IKKα↓, NF-kB↓,
210- Api,    Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer
- in-vitro, Pca, DU145
EMT↓, E-cadherin↑, Snail↓, Vim↓,
207- Api,    Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells
- in-vitro, Pca, LNCaP
PSA↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, P21↑, AR↓,
211- Api,    Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice
- in-vivo, Pca, NA
IKKα↓, NF-kB↓, cycD1/CCND1↓, COX2↓, Bcl-2↓, Bcl-xL↓, VEGF↓, PCNA↓, BAX↑,
5- Api,    Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer
- in-vitro, Pca, NA
HH↓, Gli1↓,
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
2003- Ash,    Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Nor, TIG-1 - in-vitro, PC, LNCaP
TumCD↑, selectivity↑, cFos↑, ROS↑, *ROS∅, HSP70/HSPA5↑, Apoptosis↑, ER Stress↑, TumCCA↑,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
6- Ba,    Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer
- in-vitro, Pca, NA
HH↓, Gli1↓,
2602- Ba,    Downregulation of ZFX is associated with inhibition of prostate cancer progression by baicalein
- in-vitro, Pca, NA - in-vivo, Pca, NA
ZFX↓, TumCP↓,
2603- Ba,    Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, Apoptosis↑, Cav1↓, p‑Akt↓, p‑mTOR↓, Bax:Bcl2↑, survivin↓, cl‑PARP↑, BioAv↓,
2479- Ba,    Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
- in-vitro, HCC, SW480 - in-vitro, Pca, PC3
12LOX↓, DR5↑, CHOP↑, ROS↑, *ROS∅, selectivity↑,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
1404- BBR,    Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation
- in-vitro, Pca, PC3
Apoptosis↑, *Apoptosis∅, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, eff↓, Cyt‑c↑,
2754- BetA,    Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors
- in-vitro, Pca, LNCaP
VEGF↓, survivin↓, Sp1/3/4↓, Casp↑, PARP↑, survivin↓, angioG↓,
3513- Bor,    Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Status
- in-vitro, Pca, DU145 - in-vitro, Nor, MEF
NRF2↑, selectivity↑, NQO1↑, GCLC↑, HO-1↑, TumCP↓,
3512- Bor,    Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake
- in-vitro, Pca, DU145
TumCP↓, eIF2α↑, ATF4↑, ATF6↑, GADD34↑, CHOP↓, GRP78/BiP↑, GRP94↑, Risk↓, *BMD↑, Ca+2↓, *Half-Life↝, IRE1∅, chemoP↑,
3509- Bor,    Boron and Prostate Cancer a Model for Understanding Boron Biology
- NA, Pca, NA
Ca+2↓,
3508- Bor,    The Effect of Boron on the UPR in Prostate Cancer Cells is Biphasic
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
ER Stress↑, GRP78/BiP↑, p‑eIF2α↑, UPR↑, eff↓,
4624- Bor,  VitD3,    Boron as a Medicinal Ingredient in Oral Natural Health Products
- Review, Pca, NA
*Half-Life↝, *eff↑, PSA↓, TumVol↓, IGF-1↓, *memory↓, *motorD↓,
4623- Bor,    Proteomic insights into the anti-cancer mechanisms of boron-based compounds in prostate cancer
- Review, Pca, NA
AntiCan↑,
4620- Bor,  BTZ,    Boron Compounds in the Breast Cancer Cells Chemoprevention and Chemotherapy
- Review, Var, NA - Review, Arthritis, NA - Review, Pca, NA
Risk↓, *memory↑, *Dose↑, Risk↓, other↝, *testos↑, other↝, Risk↓, TumCP↓, Apoptosis↑, eff↑,
720- Bor,    High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line
- in-vitro, Pca, DU145
ROS↑, TumCG↓, Apoptosis↑,
709- Bor,    Cellular changes in boric acid-treated DU-145 prostate cancer cells
- in-vitro, Pca, DU145
Cyc↓, MAPK↓, TumCMig↓, LAMP2↓, p‑ERK⇅, TumCM/A↑,
704- Bor,    Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid
- in-vitro, Pca, NA
PSA↓,
705- Bor,    Boric acid inhibits human prostate cancer cell proliferation
- in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
TumCP↓,
706- Bor,    Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice
- in-vivo, Pca, LNCaP
TumVol↓, IGF-1↓, PSA↓,
710- Bor,    Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells
- in-vitro, Pca, DU145
NAD↓, TumCP↓, CD38↑, Ca+2↓,
711- Bor,    Receptor Activated Ca2+ Release Is Inhibited by Boric Acid in Prostate Cancer Cells
- in-vitro, Pca, DU145
Ca+2↓,
715- Bor,    Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors
- in-vitro, Pca, HeLa
Hif1a↓,
755- Bor,    https://aacrjournals.org/cancerres/article/67/9_Supplement/4220/535557/Boric-acid-induces-apoptosis-in-both-prostate-and
- in-vitro, Pca, DU145 - in-vitro, PC, PC3
TumCG↓, Apoptosis↑,
757- Bor,    Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration
- in-vitro, Pca, DU145 - in-vitro, Nor, RWPE-1
Rho↓, Rac1↓, Cdc42↓, *eff↑,
767- Bor,    Boric acid induces cytoplasmic stress granule formation, eIF2α phosphorylation, and ATF4 in prostate DU-145 cells
- in-vitro, Pca, DU145
ER Stress↑, eIF2α↑, GRP78/BiP↑, ATF4↑,
737- Bor,    Boric Acid Activation of eIF2α and Nrf2 Is PERK Dependent: a Mechanism that Explains How Boron Prevents DNA Damage and Enhances Antioxidant Statu
- in-vitro, Pca, DU145
Risk↓, p‑eIF2α↑, ATF4↑, GADD34↑,
1450- Bos,  Cisplatin,    3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells
- in-vitro, Pca, DU145
ROS↑, MMP↓, Casp↑, Apoptosis↑, Bax:Bcl2↑, TumCCA?, cycD1/CCND1↓, CDK4↓, P21↑, p27↑, NOTCH↓, ChemoSen↑,
1449- Bos,  Chemo,    Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells
- in-vitro, Pca, PC3
TumCP↓, ChemoSen↑, MMP↝, ROS↝, Apoptosis↑,
2013- CAP,    Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, P53↑, P21↑, BAX↑, PSA↓, AR↓, NF-kB↓, Proteasome↓, TumVol↓, eff∅,
2802- CHr,    Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis
- in-vitro, Pca, DU145 - in-vivo, Pca, NA
Hif1a↓, VEGF↓, angioG↓,
2792- CHr,    Chrysin induces death of prostate cancer cells by inducing ROS and ER stress
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
DNAdam↑, TumCCA↑, MMP↓, ROS↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, PI3K↓, Akt↓, p70S6↓, MAPK↑,
1580- Citrate,    Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway
- in-vitro, Pca, PC3 - in-vivo, PC, NA - in-vitro, Pca, LNCaP - in-vitro, Pca, WPMY-1
Apoptosis↑, Ca+2↓, Akt↓, mTOR↓, selectivity↑, TumCP↓, cl‑Casp3↑, cl‑PARP↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, ATG5↑, ATG7↑, Beclin-1↑, TumAuto↑, CaMKII ↓,
2304- CUR,    Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition
- in-vitro, Lung, H1299 - in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, mTOR↓, Hif1a↓, selectivity↑, Dose↝, tumCV↓,
2811- CUR,    Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study
- Human, Pca, NA
*antiOx↑, radioP↑, RadioS∅, *TAC↑, *SOD↓,
155- CUR,    Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells
- in-vitro, Pca, PC3
p‑ERK↓, VEGF↓, angioS↑,
154- CUR,    Curcumin inhibits expression of inhibitor of DNA binding 1 in PC3 cells and xenografts
- vitro+vivo, Pca, PC3
Id1↓,
157- CUR,    Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
cJun↓, AR↓,
153- CUR,    Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo
- in-vivo, Pca, C4-2B
PSA↓, TGF-β↓, BMPs↑,
152- CUR,    Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
- in-vivo, Pca, NA
β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑,
151- CUR,    Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓,
146- CUR,  EGCG,    Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
P21↑,
131- CUR,    Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer
- vitro+vivo, Pca, LNCaP - vitro+vivo, Pca, 22Rv1
AKR1C2↓, CYP11A1↓, HSD3B↓, DHT↓, testos↓, StAR↓, SRD5A1↑,
144- CUR,  Bical,    Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C
- in-vitro, Pca, PC3 - in-vitro, NA, DU145 - in-vitro, NA, LNCaP
p‑ERK↑, p‑JNK↓, MUC1↓, p65↓,
143- CUR,    Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ER Stress↑, CHOP↑, GRP78/BiP↑, ROS↑,
141- CUR,    Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer
- in-vivo, Pca, PC3
BAX↑, Bcl-2↓,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
137- CUR,    Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
- in-vitro, Pca, DU145
NOTCH1↓, cycD1/CCND1↓, CDK2↓, P21↑, p27↑, P53↑, Bcl-2↓, Casp3↑, Casp9↑,
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑,
135- CUR,    Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TfR1/CD71↑, IRP1↑,
134- CUR,  RES,  MEL,  SIL,    Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Apoptosis↑, ROS↑, Trx1↓,
133- CUR,    Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis
- in-vitro, Pca, NA
miR-143↑, PDK1↓, FOXD3↑,
132- CUR,    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells
- in-vitro, Pca, NA
TumCCA↑, ROS↑, TumAuto↑, UPR↑,
142- CUR,    Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
- in-vivo, Pca, LNCaP
AR↓, PSA↓,
170- CUR,    Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
- vitro+vivo, Pca, PC3
TRAILR↑, BAX↑, P21↑, p27↑, NF-kB↓, cycD1/CCND1↓, VEGF↓, uPA↓, MMP2↓, MMP9↓, Bcl-2↓, Bcl-xL↓,
183- CUR,    Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
AR↓, AP-1↓, NF-kB↓, CBP↓,
182- CUR,  RES,  GI,    Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
p38↓, MKP5↑,
181- CUR,    The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo
- vitro+vivo, Pca, DU145
MMP2↓, MMP9↓,
14- CUR,    Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway
- vitro+vivo, Pca, PC3
PI3K/mTOR/ETS2↓, MDM2↓, P21↑,
158- CUR,    Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis
- vitro+vivo, Pca, LNCaP
MMP9↓, Matr↓,
169- CUR,    Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro
- in-vitro, Pca, PC3
VEGF↓,
168- CUR,    Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
- in-vitro, Pca, PC3
Akt↓, mTOR↓, AMPK↑, TAp63α↑,
167- CUR,    Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria
- in-vitro, Pca, PC3
MAPK↑, JNK↑, Casp3↑, Casp8↑, Casp9↑, AIF↑,
165- CUR,    Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, β-catenin/ZEB1↓, p‑Akt↓, GSK‐3β↓, p‑β-catenin/ZEB1↑, cycD1/CCND1↓, cMyc↓,
164- CUR,    Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro
- in-vitro, Pca, PC3
NF-kB↓, AP-1↓,
163- CUR,    Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells
- in-vitro, Pca, LNCaP
MeCP2↓, Neurog1↑, HDAC↓,
162- CUR,  EGCG,  SFN,    Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation
- in-vitro, Pca, LNCaP
p‑PDGF↓,
161- CUR,  MeSA,    Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK
- in-vitro, BC, MDA-MB-231 - in-vitro, Pca, DU145
Mcl-1↑, Mcl-1↓, MPT↑, AIF↑,
159- CUR,    Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment
- in-vitro, Pca, DU145
ROS↑, p‑Jun↑, p‑p38↑,
129- CUR,    Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation
- vitro+vivo, Pca, LNCaP
JNK↓,
130- CUR,    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
BAD↝, BAX↝, eff↑,
117- CUR,    Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells
- in-vivo, Pca, RM-1 - in-vivo, Pca, DU145
ROS↑,
118- CUR,    Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
ROS↑, Bcl-2↓, PARP↑, cDC2↓, CycB/CCNB1↓, MDM2↓,
120- CUR,    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
- Human, Pca, NA
PSA↓,
121- CUR,    Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study
- in-vivo, Pca, NA
CTC↓,
122- CUR,  isoFl,    Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen
- Human, Pca, LNCaP
PSA↓, AR↓,
123- CUR,    Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells
- in-vitro, Colon, LoVo - in-vitro, Colon, COLO205 - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
NF-kB↓,
124- CUR,    Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TGF-β↓, Wnt↓, PI3k/Akt/mTOR↓, NF-kB↓, PTEN↑, Apoptosis↑,
126- CUR,    Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
miR-34a↑, β-catenin/ZEB1↓, cMyc↓, P21↑, cycD1/CCND1↓, PCNA↓,
127- CUR,    The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis
- in-vitro, Pca, NA
Elvol3↓,
128- CUR,  RES,    Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer
- in-vivo, Pca, NA
lipid-P↓,
409- CUR,    Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity
- in-vitro, Pca, PC3 - in-vitro, BC, MDA-MB-231
GLO-I↓, GSH↓, ATP↓,
461- CUR,    Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-30a-5p↑, PCLAF↓, Bcl-2↓, Casp3↓, BAX↑, cl‑Casp3↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
481- CUR,  CHr,  Api,    Flavonoid-induced glutathione depletion: Potential implications for cancer treatment
- in-vitro, Liver, A549 - in-vitro, Pca, PC3 - in-vitro, AML, HL-60
GSH↓, mtDam↑, MMP↓, Cyt‑c↑,
1870- DCA,  Rad,    Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation
- in-vitro, Pca, PC3
TumCCA↑, Apoptosis↑, MMP↓, eff↑, RadioS↑,
1869- DCA,    Dichloroacetate induces autophagy in colorectal cancer cells and tumours
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Pca, PC3 - in-vitro, CRC, HT-29
LC3II↑, ROS↑, mTOR↓, MCT1↓, NADH:NAD↓, NAD↑, TumAuto↑, lactateProd↓, LDH↑,
4456- DFE,    Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells
- in-vitro, Pca, PC3
TumCD↑, MMP↓, mt-ROS↑, Apoptosis↑, TumCCA↑,
1184- DHA,    Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
SDC1↑, p‑PCK1↓, Akt↓, BAD↓,
2157- dietP,    Plant-Based Diets and Disease Progression in Men With Prostate Cancer
- Study, Pca, NA
TumCG↓, Risk↓, eff↑,
937- EGCG,    Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells
- in-vitro, Pca, MIA PaCa-2
lactateProd↓, Glycolysis↓, GlucoseCon↓, LDHA↓,
26- EGCG,  QC,  docx,    Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
- vitro+vivo, Pca, PC3
BAD↓, PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓,
25- EGCG,  QC,    Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
COMT↓,
24- EGCG,  GEN,  QC,    Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin
- in-vitro, Pca, 22Rv1
NQO1↑, P53↑, NQO2↑,
690- EGCG,    Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer
- in-vitro, Pca, NA
AR↓, miR-21↓, miR-330-5p↑, TumCG↓,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2499- Fenb,  VitE,    Effects of fenbendazole and vitamin E succinate on the growth and survival of prostate cancer cells
- in-vitro, Pca, PC3
TumCP∅, TumCP↓, toxicity↓, eff↑,
1065- GA,    Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression
- vitro+vivo, Pca, NA
tumCV↓, MMP↓, DNAdam↑, HDAC1↓, HDAC2↓, PCNA↓, cycD1/CCND1↓, cycE1↓, P21↑, TumVol↓,
2060- GamB,    Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells
- in-vitro, Pca, NA
TumCP↓, TumAuto↑, eff↑, ROS↑, ER Stress↑, JNK↑,
1955- GamB,    Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer
- in-vitro, Pca, NA
ROS↑, Apoptosis↑, Ferroptosis↑, Trx↓, eff↑, TrxR↓, Dose∅, MMP↓, eff↑,
1958- GamB,    Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells
- in-vitro, Pca, NA - in-vivo, NA, NA
AntiCan↑, TumCP↓, TumAuto↑, eff↑, JNK↑, ROS↑, ER Stress↑, eff↓, TumCG↓,
825- GAR,    Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling
- in-vitro, Pca, LNCaP - in-vitro, Pca, Bxpc-3 - in-vitro, Pca, PC3 - in-vitro, Pca, C4-2B
TumCG↓, Apoptosis↑, NF-kB↓,
806- GAR,    Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin
- vitro+vivo, Pca, HeLa - vitro+vivo, Cerv, SiHa
TumCI↓, TumCMig↓, TumCCA↑, Apoptosis↑, T-cadherin↑,
796- GAR,    Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression
- vitro+vivo, Pca, HeLa
HATs↓, PCAF↓, Apoptosis↑,
29- GEN,    Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway
- in-vivo, Pca, NA
HH↓, Gli1↓,
849- Gra,    Annona muricata silver nanoparticles exhibit strong anticancer activities against cervical and prostate adenocarcinomas through regulation of CASP9 and the CXCL1/CXCR2 genes axis
- in-vitro, Pca, PC3 - in-vitro, Nor, PNT1A - in-vitro, NA, HeLa
Casp9↑, CXCL1↓, *toxicity↓,
838- Gra,    Antiproliferative activity of aqueous leaf extract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes
- in-vitro, Pca, BPH1
BAX↑, Bcl-2↓, TumVol↓,
850- Gra,    Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin
- in-vitro, PC, PC3 - in-vitro, Pca, DU145
ROS∅, MMP∅, Casp3↑, Casp7↑, VEGF↓,
2437- Gra,    Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity
- in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vitro, Nor, PWR-1E
NOX↓, selectivity↑,
1644- HCAs,  PBG,    Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis
- in-vitro, Pca, LNCaP
NF-kB↓, TRAILR↑, Casp8↑, Casp3↑, MMP↓, Dose?,
2407- HCAs,    2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2
- in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
p‑PKM2↓, TumCG↓,
8- HCO3,    Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana
- in-vitro, PC, HaCaT - in-vitro, Pca, PANC1
HH↓, Gli1↓, PTCH1↓, Bcl-2↓,
4637- HT,    Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells
- in-vitro, Nor, RWPE-1 - in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3
selectivity↑, TumCMig↓, p‑Akt↓, ROS↑, CSCs↓, CD44↓, TumCP↓,
4639- HT,    Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
TumCP↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, p27↑, Apoptosis↑, Casp↑, cl‑PARP↑, Bax:Bcl2↑, p‑Akt↓, p‑STAT3↓, NF-kB↓, AR↓, ROS↑, *BioAv↓, *toxicity∅,
1278- I3C,    Indole-3-carbinol inhibits prostate cancer cell migration via degradation of beta-catenin
- in-vivo, Pca, DU145
TumCMig↓, β-catenin/ZEB1↓,
1293- Ins,    Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells
- vitro+vivo, Pca, LNCaP
TumCG↓, TumCCA↑, P21↑, CDK4↓, cycD1/CCND1↓, RB1↑, E2Fs↓,
2172- iod,    A prospective study of iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey
- Study, Pca, NA
Risk↓,
1121- JG,    Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway
- in-vitro, Pca, LNCaP
E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, GSK‐3β↑,
2351- lamb,    Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
proCasp3↓, proPARP↓, LDHA↓, Glycolysis↓, HK2↓, PKM2↓, lactateProd↓, p‑STAT3↓, cycD1/CCND1↓, cMyc↓, β-catenin/ZEB1↓, p‑GSK‐3β↓, ROS↑, eff↓,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
FASN↓, cMET↓, HGF/c-Met↓,
4687- LT,  QC,    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
- in-vitro, Pca, DU145
CSCs↓, EMT↓, MMPs↓, TumCMig↓, TumCI↓,
3274- Lyco,    Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
Akt↓, EZH2↓,
4803- Lyco,    Enhanced cytotoxic and apoptosis inducing activity of lycopene oxidation products in different cancer cell lines
- in-vitro, Pca, PC3 - in-vitro, BC, MCF-7 - in-vitro, Melanoma, A431 - in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa - in-vitro, Lung, A549
tumCV↓, GSH↓, MDA↑, ROS↑, Apoptosis↑,
4780- Lyco,    Potential inhibitory effect of lycopene on prostate cancer
- Review, Pca, NA
TumCP↓, TumCCA↑, Apoptosis↑, *neuroP↑, *NF-kB↓, *JNK↓, *NRF2↑, *BDNF↑, *Ca+2↝, *antiOx↑, *AntiCan↑, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *TNF-α↓, NF-kB↓, DNAdam↓, PSA↓, P53↓, cycD1/CCND1↓, NRF2↓, Akt2↓, PPARγ↓,
1721- Lyco,  RES,  VitC,    Lycopene, resveratrol, vitamin C and FeSO4 increase damage produced by pro-oxidant carcinogen 4-nitroquinoline-1-oxide in Drosophila melanogaster: Xenobiotic metabolism implications.
- in-vitro, Pca, PC3 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - in-vitro, BC, MCF-7 - in-vitro, Liver, HepG2
ROS↑,
971- MEL,    Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
Hif1a↓, VEGF↓, p‑p70S6↓,
526- MF,    Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Pca, HeLa - vitro+vivo, Melanoma, B16-BL6 - in-vitro, Nor, HEK293
TumCG↓, Ca+2↑, selectivity↑, *Ca+2∅, ROS↑, HSP70/HSPA5↑, AntiCan↑,
582- MF,  immuno,  VitC,    Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy
- in-vitro, Pca, TRAMP-C1 - in-vivo, NA, NA
Fenton↑, Ferroptosis↑, ROS↑, TumCG↓, Iron↑, GPx4↓,
535- MF,    Electromagnetic Fields Trigger Cell Death in Glioblastoma Cells through Increasing miR-126-5p and Intracellular Ca2+ Levels
- in-vitro, Pca, PC3 - in-vitro, GBM, A172 - in-vitro, Pca, HeLa
Apoptosis↑, miR-129-5p↑, Ca+2↑, eff↝,
522- MF,    Low Magnetic Field Exposure Alters Prostate Cancer Cell Properties
- in-vitro, Pca, PC3
MMP2↑, MMP9↑, miR-21↑, miR-155↑, miR-210↑, miR-200c↓, miR-126↓,
513- MF,    Exposure to a specific time-varying electromagnetic field inhibits cell proliferation via cAMP and ERK signaling in cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vivo, Pca, HeLa
TumCG↓, p‑ERK↑, cAMP⇅,
595- MFrot,  VitC,  MF,    The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells
- in-vitro, PC, MIA PaCa-2 - in-vitro, CRC, SW-620 - in-vitro, NA, HT1080 - in-vitro, Pca, PC3 - in-vitro, OS, U2OS - in-vitro, BC, MCF-7 - in-vitro, Nor, CCD-18Co
TumCD↑, eff↑, *TumCG∅,
1129- NarG,    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity
- in-vitro, Pca, PC3
E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,
1269- NCL,    Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
- in-vitro, Pca, DU145
STAT3↓, TumCG↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cMyc↓, Bcl-xL↓,
150- NRF,  CUR,  docx,    Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
- in-vitro, Pca, C4-2B
p‑Akt↓, p‑eIF2α↑, ER Stress↑, ATFs↑, CHOP↑, TRIB3↑,
1987- Part,  Rad,    A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Nor, PrEC
selectivity↑, RadioS↑, ROS↑, *ROS∅, NADPH↑, Trx↓, PI3K↑, Akt↑, p‑FOXO3↓, SOD2↓, Catalase↓, radioP↑, *NADPH∅, *GSH↑, *GSH/GSSG↑, *NRF2↑,
1985- Part,    KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Nor, PrEC - in-vivo, NA, NA
ROS↑, NADPH↑, RadioS↑, radioP↑, Trx↓, *ox-Keap1↑, ox-Keap1↓, rd-Keap1↑, *NRF2↑, NRF2∅, NF-kB↓,
2036- PB,    Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
- in-vitro, Pca, NA - in-vivo, NA, NA
TumCG↓, eff↑, Diff↑,
2064- PB,  Rad,    Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,
1667- PBG,    Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis
- in-vitro, Pca, LNCaP
NF-kB↓, Apoptosis↑, MMP↓,
4931- PEITC,    Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Risk↓, miR-194↑, TumCI↓, MMP2↓, MMP9↓, BMP2↓, *chemoPv↑,
4935- PEITC,    Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo
- in-vivo, Pca, LNCaP - in-vivo, Pca, PC3
Apoptosis↑, XIAP↓, survivin↓, *BioAv↑, tumCV↓, eff↓,
4939- PEITC,    Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo
- in-vitro, Pca, PC3 - ex-vivo, Nor, HUVECs
Risk↓, angioG↓, VEGF↓, TumCMig↓, Akt↓, EGF↓, TumCMig↓,
4950- PEITC,    Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential
- vitro+vivo, Pca, PC3
MMP↓, Cyt‑c↑, Smad1↑, Diablo↑, ROS↑,
4946- PEITC,    Phenethyl Isothiocyanate Inhibits Oxidative Phosphorylation to Trigger Reactive Oxygen Species-mediated Death of Human Prostate Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Apoptosis↑, TumAuto↑, ROS↑, OXPHOS↓, ATP↓, selectivity↑, ETC↓, eff↓, eff↓, BAX↑,
4945- PEITC,    Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells
- in-vitro, Pca, DU145
AntiCan↑, TumCG↓, Apoptosis↑, tumCV↓, TumCCA↑, DNAdam↑, P53↑, CDC25↓, Casp9↑, Casp8↑, mtDam↑, Cyt‑c↑,
3379- QC,    The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway
- in-vitro, Pca, LNCaP
tumCV↓, HH↓,
3373- QC,    The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway
- in-vitro, Pca, DU145
TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,
3370- QC,    Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3)
- in-vitro, Pca, PC3
MMP2↓, MMP9↓,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
74- QC,  EGCG,    Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer
- Human, Pca, NA

66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- in-vitro, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓,
67- QC,  RES,    Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
cJun↑, AR↓,
68- QC,  BaP,    Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, PrEC
PrxI∅, PrxII∅, *toxicity↓, ROS↓, ROS↑, ROS∅, chemoP↑, PrxII↑, i-H2O2↓,
69- QC,    Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
TRAIL↑, Casp3↑, Casp9↑, Casp8↑, DR5↑,
70- QC,    Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
PSA↓, AR↓, NKX3.1↓, HK2↓,
71- QC,    Role of Bax in quercetin-induced apoptosis in human prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PrEC - in-vitro, Pca, YPEN-1 - in-vitro, Pca, HCT116
Casp8↑, Casp9↑, PARP↑, BAD↓, BAX↑, PI3K/Akt↓,
72- QC,    Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity
- in-vitro, Pca, PECs - in-vitro, Pca, LNCaP - in-vitro, Pca, NIH-3T3
AR↓,
73- QC,    The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
HSP90↓, Casp3↑, Casp9↑,
75- QC,    Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
- in-vitro, Pca, HEK293 - in-vitro, NA, 22Rv1 - in-vitro, NA, C4-2B
hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓,
76- QC,    Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy
- in-vitro, Pca, PC3
aSmase↝, Diablo↝, Fas↝, Hsc70↝, Hif1a↝, Mcl-1↝, HSP90↝, FLT4↝, EphB4↝, DNA-PK↝, PARP1↝, ATM↝, XIAP↝, PLC↝, GnT-V↝, heparanase↝, NM23↝, CSR1↝, SPP1↝, DNMT1↝, HDAC4↝, CXCR4↝, β-catenin/ZEB1↝, FBXW7↝, AMACR↝, cycD1/CCND1↝, IGF-1R↝, IMPDH1↝, IMPDH2↝, HEC1↝, NHE1↝, NOS2↝,
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, Nanog↓,
78- QC,    Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells
- in-vitro, Pca, PC3
IGF-1↓, IGF-2↓, IGFBP3↑, Bcl-2↓, Bcl-xL↓, Casp3↑,
79- QC,    Chemopreventive Effect of Quercetin in MNU and Testosterone Induced Prostate Cancer of Sprague-Dawley Rats
- in-vivo, Pca, NA
GSH↑, SOD↑, Catalase↑, GPx↑, GSR↑,
80- QC,    Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway
- in-vitro, Pca, PC3
Vim↓, ERK↓, Snail↓, Slug↓, Twist↓, EGFR↓, p‑Akt↓, EGFR↓, N-cadherin↓,
81- QC,  EGCG,    Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea
- in-vivo, Pca, NA
COMT↓, MRP1↓, Ki-67↓, Bax:Bcl2↑, AR↓, Akt↓, p‑ERK↓, COMT↓, eff↑,
60- QC,  EGCG,  isoFl,  isoFl,  isoFl  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓,
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓,
63- QC,    Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells
- in-vitro, Pca, NA
RAGE↓, PI3K↓, mTOR↓, Akt↓, Apoptosis↑, TumAuto↑,
83- QC,    Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3
- in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, BAX↑, IGFBP3↑,
100- QC,    Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓,
99- QC,    Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1
- in-vitro, Pca, PC3
EMT↓, E-cadherin↑, N-cadherin↓, Ki-67↓, PI3K/Akt↓, MALAT1↓,
38- QC,    Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS↑, GSH↓, PI3K/Akt⇅,
138- QC,  CUR,    Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
DNMTs↓,
84- QC,    Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression
- in-vitro, Pca, PC3
P21↑, cDC2↓, CDK1↓, CycB/CCNB1↓, Casp3↑, Bcl-2↓, Bcl-xL↓, BAX↑, pRB↓,
85- QC,    Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)
- in-vitro, Pca, PC3
uPA↓, uPAR↓, EGFR↓, NRAS↓, Jun↓, NF-kB↓, β-catenin/ZEB1↓, p38↑, MAPK↑, cJun↓, cFos↓, Raf↓,
86- QC,    Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3)
- in-vitro, Pca, PC3
BAD↑, IGFBP3↑, Cyt‑c↑, cl‑Casp9↑, Casp10↑, cl‑PARP↑, Casp3↑, IGF-1R↓, PI3K↓, p‑Akt↓, cycD1/CCND1↓, IGF-1↓, IGF-2↓, IGF-1R↓,
87- QC,    Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, BAX↑, PUMA⇅, β-catenin/ZEB1↓, Shc↓, TAp63α↑, MAPK↑, p‑p42↑, p‑p44↑, BIM↑,
88- QC,  PacT,    Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production
- vitro+vivo, Pca, PC3
ROS↑, ER Stress↑,
89- QC,  doxoR,    Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met
- in-vitro, Pca, PC3
PI3K/Akt↓, cMET↓, Casp3↑, Casp9↑, MMP↓,
90- QC,  HP,    Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21
- in-vitro, Pca, PC3
ROS↑, cl‑Casp3↑, cl‑PARP↑, miR-21↓, PDCD4↑,
91- QC,    The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells
- in-vitro, Pca, PC3
CDK2↓, cycE/CCNE↓, cycD1/CCND1↓, ATFs↑, GRP78/BiP↑, Bcl-2↓, BAX↑, Casp3↑, Casp8↑, Casp9↑, ER Stress↑, CHOP↑,
92- QC,    Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways
- vitro+vivo, Pca, HUVECs - vitro+vivo, Pca, PC3
VEGF↓, HemoG↓, Akt↓, mTOR↓, P70S6K↓,
93- QC,    Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-cancer Effects in PC-3 Cells
- in-vitro, Pca, PC3
hnRNPA1↓, Casp3↑, Casp7↑,
94- QC,  HPT,    Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, JCA-1
HSP70/HSPA5↓,
95- QC,    Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent
- in-vitro, Pca, PC3
p‑ERK↓, p‑STAT3↓, p‑Akt↓, N-cadherin↓, Vim↓, cycD1/CCND1↓, Snail↓, Slug↓, Twist↓, PCNA↓,
96- QC,  docx,    Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp↓,
97- QC,  HPT,    Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
- in-vitro, Pca, PC3
HSP72↑,
82- QC,  AG,    Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells
- in-vitro, Pca, NA
AR↓, PI3K/Akt↓, miR-21↓, STAT3↓, BAD↓, PRAS40↓, GSK‐3β↓, PSA↓, NKX3.1↑, Bax:Bcl2↑, miR-19b↓, miR-148a↓, AMPKα↓,
156- Ralox,  Tam,  GEN,  CUR,    Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ERβ↑,
105- RES,  QC,    The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell
- in-vitro, Pca, CD133+
N-cadherin↓, TNF-α↓, ACTA2↓,
881- RES,    Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, PANC1 - in-vitro, Pca, DU145
TumCCA↑, cycD1/CCND1↓, Bcl-xL↓, Mcl-1↓, other↓,
3078- RES,    The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
- Review, Pca, NA
*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,
3091- RES,    Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, ALVA-41
CK2↓, Apoptosis↑,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3033- RosA,    Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP - vitro+vivo, NA, NA
ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP↑, PERK↓, GRP78/BiP↑, PSA↓,
3029- RosA,    Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCP↓, tumCV↓, Apoptosis↑, HDAC2↓, PCNA↓, cycD1/CCND1↓, cycE/CCNE↓, P21↑, DNAdam↑, Casp3↑,
2040- SAHA,    The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
- in-vitro, Pca, LNCaP - in-vitro, CRC, T24 - in-vitro, BC, MCF-7
HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,
4908- Sal,    Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
tumCV↓, ROS↑, lipid-P↑, UPR↑, ER Stress↑, NRF2↓, NADPH↓, HO-1↓, SOD↓, Catalase↓, GPx↓, eff↓, TumCP↓,
4999- Sal,    Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells
- in-vitro, Pca, PC3
Bacteria↓, CSCs↓, ER Stress↑,
1706- Se,    Selenium in Prostate Cancer: Prevention, Progression, and Treatment
- Review, Pca, NA
Risk∅, ChemoSen↑, Risk↓, toxicity↝, Risk↑, eff↑, *toxicity↑, RadioS↑, eff↓, eff↑, ChemoSen↑, ChemoSideEff↓,
4744- Se,  Chemo,  antiOx,    Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: A good thing?
- Review, Pca, NA
Risk↓, chemoP↑,
4501- Se,    Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines
- in-vitro, GBM, A172 - in-vitro, Colon, Caco-2 - in-vitro, Pca, DU145 - in-vitro, BC, MCF-7 - in-vitro, Nor, L929
*BioAv↑, selectivity↑, AntiCan↑, Apoptosis↑, CHOP↑, GADD34↑, BIM↑, PUMA↑, Ca+2↝,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
3192- SFN,    Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention
- in-vitro, Pca, PC3
Sp1/3/4↓, selectivity↑, NRF2↑, HDAC↓, DNMTs↓, TumCCA↑, selectivity↑, HO-1↑, NQO1↑, CDK2↓, TumCP↓, BID↑, Smad1↑, Diablo↑, ICAD↑, Cyt‑c↑, IAP1↑, HSP27↑, *Cyt‑c↓, *IAP1↓, *HSP27↓, survivin↓, CDK4↓, VEGF↓, AR↓,
2403- SFN,    Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane
- in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3 - in-vivo, NA, NA
ECAR↓, HK2↓, PKM2↓, LDHA↓, Glycolysis↓, Warburg↓,
2404- SFN,    Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism
- in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
ACC1↓, FASN↓, CPT1A↓, β-oxidation↓, SREBP1?, HK2↓, PKM2↓, LDHA↓, Glycolysis↓,
2446- SFN,  CAP,    The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor
- in-vitro, Pca, LNCaP
AR↓, Bcl-xL↓, TumCP↓, Glycolysis↓, HK2↓, PKA↓, Hif1a↓, PSA↓, ECAR↓, BioAv↑, BioAv↓, *toxicity↓,
2406- SFN,    Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach
- Review, Pca, NA
HK2↓, PKM2↓, LDHA↓, Glycolysis↓, LAMP2↑, Hif1a↓, DNAdam↓, DNArepair↓, Dose↝,
1453- SFN,    Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,
1481- SFN,  docx,    Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
ChemoSen↑, Casp3↑, ROS↑, Casp8↑, Cyt‑c↑, Glycolysis↓, GSH↓, GSH/GSSG↓, *toxicity↓,
1497- SFN,    Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells
- in-vitro, Nor, PrEC - in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
HDAC↓, selectivity↑, TumCCA↑, Apoptosis↑, selectivity↑, H3↑, P21↑, selectivity↑,
1468- SFN,    Cellular responses to dietary cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
ROS↑, DNAdam↑, MMP↓, Cyt‑c↑, TumCCA↑,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
2164- SFN,  dietP,    Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice
- in-vitro, Pca, NA
HDAC↓, Dose↝, Risk↓, TumCP↓, H3↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
318- SNP,    Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells
- in-vitro, Pca, PC3
lysoM↓, lysosome↓, AMPKα↑, TumAuto↑, mTOR↑,
4435- SNP,  Gluc,    Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
selectivity↑, ROS↑, mtDam↑, TumCCA↑, TumCP↓, Apoptosis↑, MMP↓,
4584- SNP,    Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells
- in-vitro, Pca, DU145
selectivity↑, ROS↑, BAX↑, cl‑Casp3↑, p‑PARP↑, TumCCA↑, cycD1/CCND1↓, p27↑, P21↑, AntiCan↑,
4411- SNP,    Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities
- in-vitro, Lung, A549 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, PC3 - in-vitro, Nor, HEK293
AntiCan↑, selectivity↑, Apoptosis↑, TumCCA↑, Bacteria↓, tumCV↓, selectivity↑, Apoptosis↑, TumCCA↑,
4892- Sper,  erastin,    Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer
- in-vitro, Pca, PC3 - in-vivo, Pca, NA
Ferroptosis↑, lipid-P↑, Iron↑, eff↑, HO-1↑, NRF2↑, ROS↑, AntiTum↑, eff↓,
112- SuD,    Inhibition of Gli/hedgehog signaling in prostate cancer cells by “cancer bush” Sutherlandia frutescens extract
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
HH↓, Gli1↓, PTCH1↓,
1137- Taur,    Taurine Attenuates Epithelial-Mesenchymal Transition-Related Genes in Human Prostate Cancer Cells
- in-vitro, Pca, NA
N-cadherin↓, Twist↓, Zeb1↓, Snail↓, Vim↓, E-cadherin↑,
139- Tomatine,  CUR,    Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
- in-vitro, Pca, PC3
NF-kB↓, Bcl-2↓, p‑Akt↓, p‑ERK↓,
113- TQ,    Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
- vitro+vivo, Pca, C4-2B
HH↓, Shh↓, Gli1↓,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,
1934- TQ,    Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species
- in-vitro, Pca, PC3 - in-vitro, Pca, C4-2B
ROS↑, GSH↓, eff↓,
119- UA,  CUR,  RES,    Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, p‑STAT3↓, Src↓, AMPK↑,
4854- Uro,    Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
- Review, Pca, NA
AR↓, ROS↓, Apoptosis↑, selectivity↑, Dose↑, MDA↓, SOD↑, GPx↑, ROS↑, Casp3↑, Casp9↑,
4843- Uro,    The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide
- in-vitro, Pca, LNCaP
TumCP↓, eff↑, ChemoSen↝,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,
4834- Uro,    Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
- Human, Pca, NA
eff↑, NK cell↑,
114- VitC,  QC,    Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative stress
- in-vitro, Pca, PC3 - in-vitro, NA, DU145
GPx↓, GSR↓, NQO1↓, NRF2↓, ROS↑,
300- VitC,  ALA,    Combination of High-Dose Parenteral Ascorbate (Vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect But Increased Toxicity in Preclinical Cancer Models
- in-vitro, BC, MDA-MB-231 - in-vitro, Colon, HCT116 - in-vitro, Ovarian, PANC1 - in-vitro, Pca, PC3
TumCG∅,
1825- VitK2,    Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial
- Analysis, Pca, NA
Risk∅,
1824- VitK2,    Vitamin K and its analogs: Potential avenues for prostate cancer management
- Review, Pca, NA
AntiCan↑, toxicity∅, Risk↓, Apoptosis↑, ROS↑, TumCCA↑, eff↑, DNAdam↑, MMP↓, Cyt‑c↑, pro‑Casp3↑, FasL↑, Fas↑, TumAuto↑, ChemoSen↑, RadioS↑,
1839- VitK3,    Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells
- in-vitro, Pca, NA
TumCP↓, Apoptosis↑, TumCCA↑, ROS↑, eff↓, AR↓, Trx↓, Bcl-2↓,
1837- VitK3,  VitC,    Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death
- in-vivo, Pca, NA
eff↑, ROS↑, TumAuto↑,
1759- WBV,    Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study
- Study, Pca, NA
Risk↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 261

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 2,   Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 3,   GCLC↑, 1,   GPx↓, 2,   GPx↑, 2,   GPx4↓, 1,   GSH↓, 7,   GSH↑, 2,   GSH∅, 1,   GSH/GSSG↓, 1,   GSR↓, 1,   GSR↑, 1,   GSTP1/GSTπ↓, 1,   i-H2O2↓, 1,   HO-1↓, 2,   HO-1↑, 3,   HO-2↑, 1,   Iron↑, 2,   IRP1↑, 1,   ox-Keap1↓, 1,   rd-Keap1↑, 1,   lipid-P↓, 1,   lipid-P↑, 3,   MDA↓, 2,   MDA↑, 1,   NQO1↓, 1,   NQO1↑, 3,   NRF2↓, 4,   NRF2↑, 4,   NRF2∅, 1,   OXPHOS↓, 1,   PrxI∅, 1,   PrxII↑, 1,   PrxII∅, 1,   ROS↓, 5,   ROS↑, 54,   ROS⇅, 3,   ROS↝, 1,   ROS∅, 2,   mt-ROS↑, 1,   SOD↓, 2,   SOD↑, 4,   SOD1↑, 1,   SOD2↓, 1,   Trx↓, 4,   Trx1↓, 1,   TrxR↓, 1,  

Metal & Cofactor Biology ⓘ

TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 3,   ATP↓, 2,   BCR↓, 1,   CDC16↓, 1,   CDC25↓, 1,   EGF↓, 2,   ETC↓, 1,   FGFR1↓, 1,   MEK↓, 1,   MKP5↑, 1,   MMP↓, 20,   MMP↝, 1,   MMP∅, 1,   MPT↑, 1,   mtDam↑, 3,   p‑p42↑, 1,   Raf↓, 2,   XIAP↓, 5,   XIAP↝, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   ACC↓, 1,   ACC1↓, 1,   AKT1↓, 1,   AMACR↝, 1,   AMPK↑, 2,   ATG7↑, 1,   cAMP⇅, 1,   Cav1↓, 2,   cMyc↓, 7,   CPT1A↓, 1,   ECAR↓, 2,   Elvol3↓, 1,   FASN↓, 3,   GLO-I↓, 1,   GlucoseCon↓, 2,   GlucoseCon∅, 1,   Glycolysis↓, 8,   HK2↓, 7,   lactateProd↓, 4,   lactateProd∅, 1,   LDH↑, 2,   LDHA↓, 5,   NAD↓, 1,   NAD↑, 1,   NADH:NAD↓, 1,   NADPH↓, 2,   NADPH↑, 2,   p‑PCK1↓, 1,   PDK1↓, 1,   PI3K/Akt↓, 7,   PI3K/Akt⇅, 1,   PI3k/Akt/mTOR↓, 1,   PI3K/mTOR/ETS2↓, 1,   PKM2↓, 5,   p‑PKM2↓, 1,   PPARγ↓, 1,   SIRT1↑, 1,   SREBP1?, 1,   TumCM/A↑, 1,   Warburg↓, 1,   β-oxidation↓, 1,  

Cell Death ⓘ

Akt↓, 13,   Akt↑, 1,   p‑Akt↓, 12,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 47,   aSmase↝, 1,   BAD↓, 4,   BAD↑, 1,   BAD↝, 1,   Bak↑, 2,   BAX↑, 24,   BAX↝, 1,   Bax:Bcl2↑, 8,   Bcl-2↓, 29,   Bcl-xL↓, 15,   BID↑, 2,   BIM↑, 5,   BMP2↓, 1,   Casp↑, 6,   Casp10↑, 1,   Casp3↓, 2,   Casp3↑, 25,   cl‑Casp3↑, 7,   proCasp3↓, 1,   pro‑Casp3↑, 1,   Casp7↑, 5,   Casp8↑, 10,   Casp9↑, 15,   cl‑Casp9↑, 2,   CBP↓, 1,   CBP↑, 1,   CK2↓, 1,   CSR1↝, 1,   Cyt‑c↑, 13,   Diablo↑, 2,   Diablo↝, 1,   DR4↑, 1,   DR5↑, 5,   Fas↑, 1,   Fas↝, 1,   FasL↑, 2,   Ferroptosis↑, 3,   GADD34↑, 3,   HGF/c-Met↓, 1,   IAP1↑, 1,   ICAD↑, 1,   JNK↓, 1,   JNK↑, 6,   p‑JNK↓, 1,   MAPK↓, 3,   MAPK↑, 5,   Mcl-1↓, 5,   Mcl-1↑, 1,   Mcl-1↝, 1,   MCT1↓, 1,   MDM2↓, 4,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   NOXA↑, 2,   p27↑, 6,   p38↓, 2,   p38↑, 3,   p‑p38↑, 1,   PDCD4↑, 1,   Proteasome↓, 1,   PUMA↑, 3,   PUMA⇅, 1,   survivin↓, 9,   TRAIL↑, 1,   TRAILR↑, 2,   TumCD↑, 3,  

Kinase & Signal Transduction ⓘ

AMPKα↓, 1,   AMPKα↑, 1,   CaMKII ↓, 1,   CDC7↓, 1,   FOXD3↑, 1,   HER2/EBBR2↓, 3,   p70S6↓, 1,   p‑p70S6↓, 1,   RTK-RAS↓, 1,   Sp1/3/4↓, 3,   TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 2,   cJun↑, 1,   EZH2↓, 1,   H3↓, 1,   H3↑, 2,   H4↑, 1,   HATs↓, 1,   Matr↓, 1,   MeCP2↓, 1,   miR-129-5p↑, 1,   miR-143↑, 1,   miR-205↑, 1,   miR-21↓, 4,   miR-21↑, 2,   miR-30a-5p↑, 1,   other↓, 1,   other↝, 2,   PCAF↓, 1,   pRB↓, 1,   p‑pRB↓, 1,   Prot↓, 1,   Shc↓, 1,   SPP1↝, 1,   tumCV↓, 13,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   ATFs↑, 2,   CHOP↓, 1,   CHOP↑, 8,   eIF2α↑, 3,   p‑eIF2α↑, 4,   ER Stress↑, 14,   GRP78/BiP↑, 8,   GRP94↑, 1,   Hsc70↝, 1,   HSP27↑, 1,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↑, 2,   HSP72↑, 1,   HSP90↓, 1,   HSP90↝, 1,   IRE1∅, 1,   NQO2↑, 1,   PERK↓, 1,   PERK↑, 1,   UPR↑, 5,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↓, 1,   Beclin-1↑, 2,   LAMP2↓, 1,   LAMP2↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3B↑, 1,   LC3B-II↑, 1,   LC3II↑, 1,   lysoM↓, 1,   lysosome↓, 1,   p62↓, 2,   p62↑, 2,   TumAuto↑, 11,  

DNA Damage & Repair ⓘ

ATM↝, 1,   BRCA1↑, 1,   CUL4B↑, 1,   DNA-PK↝, 1,   DNAdam↓, 2,   DNAdam↑, 9,   DNArepair↓, 1,   DNMT1↝, 1,   DNMTs↓, 2,   NKX3.1↓, 2,   NKX3.1↑, 1,   P53↓, 1,   P53↑, 12,   p‑P53↑, 3,   PARP↓, 1,   PARP↑, 6,   p‑PARP↑, 3,   cl‑PARP↑, 7,   proPARP↓, 1,   PARP1↑, 1,   PARP1↝, 1,   PCLAF↓, 1,   PCNA↓, 6,  

Cell Cycle & Senescence ⓘ

CDK1↓, 4,   CDK1↑, 1,   CDK2↓, 7,   CDK2↑, 2,   CDK4↓, 4,   Cyc↓, 2,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 20,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 5,   cycE1↓, 1,   cycF↓, 1,   E2Fs↓, 2,   p19↑, 1,   P21↑, 23,   RB1↑, 2,   TAp63α↑, 2,   TumCCA?, 1,   TumCCA↑, 26,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   AR-FL↓, 1,   AR-V7↑, 1,   CD44↓, 1,   cDC2↓, 3,   cFos↓, 2,   cFos↑, 1,   cMET↓, 2,   CSCs↓, 5,   Diff↓, 1,   Diff↑, 3,   EMT↓, 12,   EP300↑, 1,   EpCAM↓, 1,   ERK↓, 3,   ERK↑, 1,   p‑ERK↓, 5,   p‑ERK↑, 3,   p‑ERK⇅, 1,   FBXW7↝, 1,   FGF↓, 2,   FOXO3↑, 1,   p‑FOXO3↓, 1,   Gli1↓, 7,   GSK‐3β↓, 2,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 8,   HDAC1↓, 2,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC4↝, 1,   HH↓, 8,   Id1↓, 1,   IGF-1↓, 4,   IGF-1R↓, 2,   IGF-1R↝, 1,   IGF-2↓, 2,   IGFBP3↑, 4,   Jun↓, 1,   p‑Jun↑, 1,   miR-194↑, 1,   miR-330-5p↑, 1,   miR-34a↑, 1,   mTOR↓, 8,   mTOR↑, 1,   p‑mTOR↓, 1,   p‑mTOR↑, 1,   Nanog↓, 2,   Neurog1↑, 1,   NF2↑, 1,   NOTCH↓, 2,   NOTCH1↓, 2,   NRAS↓, 1,   P70S6K↓, 1,   PI3K↓, 7,   PI3K↑, 1,   p‑PI3K↓, 1,   PTCH1↓, 3,   PTEN↑, 2,   RAS↓, 1,   SCF↓, 1,   Shh↓, 3,   SOX2↓, 1,   Src↓, 2,   STAT3↓, 5,   p‑STAT3↓, 4,   TCF↓, 1,   TumCG↓, 22,   TumCG↑, 1,   TumCG∅, 1,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,   ZFX↓, 1,  

Migration ⓘ

ACTA2↓, 1,   AKR1C2↓, 1,   Akt2↓, 1,   AP-1↓, 2,   Ca+2↓, 5,   Ca+2↑, 2,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   CD38↑, 1,   Cdc42↓, 1,   CDK4/6↓, 3,   CXCL12↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 8,   EphB4↝, 1,   FAK↓, 2,   GnT-V↝, 1,   heparanase↝, 1,   hnRNPA1↓, 2,   Ki-67↓, 4,   LEF1↓, 2,   MALAT1↓, 1,   miR-148a↓, 1,   miR-155↑, 1,   miR-19b↓, 1,   miR-200c↓, 1,   MMP2↓, 7,   MMP2↑, 1,   MMP9↓, 9,   MMP9↑, 1,   MMPs↓, 3,   MSH2↑, 1,   MUC1↓, 1,   N-cadherin↓, 8,   NM23↝, 1,   p‑p44↑, 1,   PDGF↓, 1,   p‑PDGF↓, 1,   PKA↓, 1,   Rac1↓, 1,   RAGE↓, 1,   Rho↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   SDC1↑, 1,   Sharpin↓, 1,   Slug↓, 6,   Smad1↑, 2,   SMAD2↓, 2,   SMAD3↓, 2,   Snail↓, 11,   T-cadherin↑, 1,   TET1↑, 1,   TGF-β↓, 6,   TIMP2↑, 1,   TIMP3↑, 1,   TRIB3↑, 1,   TSC1↑, 1,   TSP-1↑, 1,   TumCI↓, 8,   TumCMig↓, 13,   TumCP↓, 29,   TumCP∅, 1,   TumMeta↓, 1,   Twist↓, 5,   TXNIP↑, 1,   uPA↓, 4,   uPAR↓, 2,   Vim↓, 8,   Zeb1↓, 1,   β-catenin/ZEB1↓, 10,   β-catenin/ZEB1↝, 1,   p‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   angioS↑, 1,   ATF4↑, 4,   EGFR↓, 7,   FLT4↝, 1,   HIF-1↓, 1,   Hif1a↓, 7,   Hif1a↑, 3,   Hif1a↝, 1,   miR-126↓, 1,   miR-210↑, 1,   VEGF↓, 17,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

NHE1↝, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CRP↓, 1,   CXCL1↓, 1,   CXCR4↓, 3,   CXCR4↝, 1,   IKKα↓, 2,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 2,   IκB↓, 1,   NF-kB↓, 25,   NK cell↑, 1,   p65↓, 2,   PSA↓, 18,   TLR4↓, 1,   TNF-α↓, 3,  

Cellular Microenvironment ⓘ

NOX↓, 1,   PLC↝, 1,  

Synaptic & Neurotransmission ⓘ

MAOA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 24,   COMT↓, 3,   CYP11A1↓, 1,   DHT↓, 1,   ERβ↑, 1,   FKBP5↓, 1,   HSD3B↓, 1,   SRD5A1↑, 1,   StAR↓, 1,   testos↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 9,   ChemoSen↝, 1,   Dose?, 1,   Dose↑, 1,   Dose↝, 4,   Dose∅, 2,   eff↓, 16,   eff↑, 24,   eff↝, 1,   eff∅, 1,   MRP1↓, 1,   RadioS↑, 7,   RadioS∅, 1,   selectivity↓, 1,   selectivity↑, 26,  

Clinical Biomarkers ⓘ

AR↓, 24,   BMPs↑, 1,   BRCA1↑, 1,   CRP↓, 1,   CTC↓, 1,   EGFR↓, 7,   EZH2↓, 1,   HEC1↝, 1,   HemoG↓, 1,   HER2/EBBR2↓, 3,   IL6↓, 2,   Ki-67↓, 4,   LDH↑, 2,   NOS2↝, 1,   PSA↓, 18,   RAGE↓, 1,   TRIB3↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 9,   AntiTum↑, 1,   chemoP↑, 5,   ChemoSideEff↓, 1,   IMPDH1↝, 1,   IMPDH2↝, 1,   PRAS40↓, 1,   radioP↑, 3,   Risk↓, 14,   Risk↑, 1,   Risk∅, 2,   TGFβR1↑, 1,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 6,   TumW↓, 2,   UBE2C↓, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 2,  
Total Targets: 541

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 3,   GSH↑, 1,   GSH/GSSG↑, 1,   ox-Keap1↑, 1,   NRF2↑, 3,   ROS↓, 1,   ROS∅, 3,   SOD↓, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis ⓘ

NADPH∅, 1,  

Cell Death ⓘ

Apoptosis∅, 1,   Cyt‑c↓, 1,   IAP1↓, 1,   JNK↓, 1,  

Protein Folding & ER Stress ⓘ

HSP27↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG∅, 1,  

Migration ⓘ

Ca+2↝, 1,   Ca+2∅, 1,  

Immune & Inflammatory Signaling ⓘ

IL1↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Hormonal & Nuclear Receptors ⓘ

testos↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 3,   Dose↑, 1,   eff↑, 2,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

BMD↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   memory↓, 1,   memory↑, 1,   motorD↓, 1,   neuroP↑, 1,   toxicity↓, 5,   toxicity↑, 1,   toxicity∅, 1,  
Total Targets: 42

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page